

# Simon P Robinson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9144973/simon-p-robinson-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

116  
papers

6,008  
citations

35  
h-index

75  
g-index

136  
ext. papers

7,060  
ext. citations

7.4  
avg, IF

5.06  
L-index

#	Paper	IF	Citations
116	TMOD-03. A NOVEL MB GR3 TRANSGENIC MOUSE MODEL IS GENERATED BY MYCN AND P53 DEFECTS IN VENTRICULAR ZONE PROGENITORS.. <i>Neuro-Oncology</i> , <b>2021</b> , 23, i36-i36	1	1
115	Hypoxia and its therapeutic possibilities in paediatric cancers. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 539-551	5.17	13
114	Noninvasive MRI Native T Mapping Detects Response to -targeted Therapies in the Th- Model of Neuroblastoma. <i>Cancer Research</i> , <b>2020</b> , 80, 3424-3435	10.1	9
113	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 5875-5892	15.9	21
112	MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma. <i>Oncotarget</i> , <b>2020</b> , 11, 2141-2159	3.3	7
111	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , <b>2020</b> , 10, 942-963	24.4	65
110	DIPG-25. GENETIC ALTERATIONS TARGETING THE MAPK PATHWAY CONFERS PRECLINICAL SENSITIVITY TO TRAMETINIB IN A CO-CLINICAL TRIAL IN DIPG. <i>Neuro-Oncology</i> , <b>2019</b> , 21, ii74-ii74	1	78
109	MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment. <i>Cancer Research</i> , <b>2019</b> , 79, 2978-2991	10.1	8
108	Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Noninvasive Magnetic Resonance Elastography. <i>Cancer Research</i> , <b>2019</b> , 79, 5874-5883	10.1	16
107	Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis. <i>Cancer Research</i> , <b>2019</b> , 79, 5382-5393	10.1	21
106	Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI. <i>British Journal of Radiology</i> , <b>2019</b> , 92, 20180642	3.4	58
105	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. <i>Science</i> , <b>2018</b> , 359, 920-926	33.3	712
104	Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	11
103	Investigating Low-Velocity Fluid Flow in Tumors with Convection-MRI. <i>Cancer Research</i> , <b>2018</b> , 78, 1859-1872	10.1	18
102	Assessment of the direct effects of DDAH I on tumour angiogenesis in vivo. <i>Angiogenesis</i> , <b>2018</b> , 21, 737-749	1.96	5
101	Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma. <i>Brain Pathology</i> , <b>2018</b> , 28, 475-483	6	12
100	Characterisation of fibrosis in chemically-induced rat mammary carcinomas using multi-modal endogenous contrast MRI on a 1.5T clinical platform. <i>European Radiology</i> , <b>2018</b> , 28, 1642-1653	8	3

99	Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 271	5.3	7
98	Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI: Comparison with Intrinsic Susceptibility MRI and Pathology. <i>Radiology</i> , <b>2018</b> , 288, 739-747	20.5	21
97	Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. <i>Molecular Oncology</i> , <b>2017</b> , 11, 996-1006	7.9	4
96	Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma with Susceptibility Contrast MRI. <i>Cancer Research</i> , <b>2017</b> , 77, 4127-4134	10.1	23
95	Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4233-4241	12.9	24
94	Correlation of Ultrasound Shear Wave Elastography with Pathological Analysis in a Xenographic Tumour Model. <i>Scientific Reports</i> , <b>2017</b> , 7, 165	4.9	17
93	Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging. <i>Scientific Reports</i> , <b>2017</b> , 7, 8215	4.9	7
92	Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI. <i>Neoplasia</i> , <b>2017</b> , 19, 684-694	6.4	11
91	Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 791-800	8.7	5
90	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 169-186	19.4	532
89	Multi-Channel Optical Coherence Elastography Using Relative and Absolute Shear-Wave Time of Flight. <i>PLoS ONE</i> , <b>2017</b> , 12, e0169664	3.7	4
88	Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 691-702	8.7	16
87	HG-99A PATIENT-DERIVED PAEDIATRIC HIGH GRADE GLIOMA AND DIPG CELL CULTURE PANEL RECAPITULATING THE GENOTYPIC AND PHENOTYPIC DIVERSITY OF THE DISEASE. <i>Neuro-Oncology</i> , <b>2016</b> , 18, iii71.3-iii71	1	78
86	Investigating the Vascular Phenotype of Subcutaneously and Orthotopically Propagated PC3 Prostate Cancer Xenografts Using Combined Carbogen Ultrasound Superparamagnetic Iron Oxide MRI. <i>Topics in Magnetic Resonance Imaging</i> , <b>2016</b> , 25, 237-243	2.3	3
85	Investigating the role of tumour cell derived iNOS on tumour growth and vasculature in vivo using a tetracycline regulated expression system. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 2678-87	7.5	12
84	p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance. <i>Cancer Research</i> , <b>2016</b> , 76, 3025-35	10.1	25
83	Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models. <i>Cancer Research</i> , <b>2016</b> , 76, 787-95	10.1	104
82	Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. <i>Oncotarget</i> , <b>2016</b> , 7, 57525-57544	3.3	32

81	PCM-08IN VIVOMAGNETIC RESONANCE IMAGING IDENTIFIES CLINICAL PHENOTYPES OF PAEDIATRIC GLIOBLASTOMA IN AN ORTHOTOPIC MOUSE XENOGRAFT MODEL. <i>Neuro-Oncology</i> , <b>2016</b> , 18, iii140.4-iii141	1	78
80	Modulation of renal oxygenation and perfusion in rat kidney monitored by quantitative diffusion and blood oxygen level dependent magnetic resonance imaging on a clinical 1.5T platform. <i>BMC Nephrology</i> , <b>2016</b> , 17, 142	2.7	5
79	Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737). <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 5221-37	8.3	16
78	Repeatability and sensitivity of T2* measurements in patients with head and neck squamous cell carcinoma at 3T. <i>Journal of Magnetic Resonance Imaging</i> , <b>2016</b> , 44, 72-80	5.6	24
77	Investigating intracranial tumour growth patterns with multiparametric MRI incorporating Gd-DTPA and USPIO-enhanced imaging. <i>NMR in Biomedicine</i> , <b>2016</b> , 29, 1608-1617	4.4	11
76	Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 5100-9	12.9	39
75	Detecting microvascular changes in the mouse spleen using optical computed tomography. <i>Microvascular Research</i> , <b>2015</b> , 101, 96-102	3.7	2
74	Exploring the biomechanical properties of brain malignancies and their pathologic determinants in vivo with magnetic resonance elastography. <i>Cancer Research</i> , <b>2015</b> , 75, 1216-1224	10.1	64
73	Apparent diffusion coefficient is highly reproducible on preclinical imaging systems: Evidence from a seven-center multivendor study. <i>Journal of Magnetic Resonance Imaging</i> , <b>2015</b> , 42, 1759-64	5.6	13
72	Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo. <i>Bone</i> , <b>2015</b> , 81, 581-592	4.7	31
71	Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. <i>Cancer Cell</i> , <b>2015</b> , 27, 72-84	24.3	122
70	Abstract 3271: Novel orthotopic pediatric high grade glioma xenografts evaluated with magnetic resonance imaging mimic human disease <b>2015</b> ,		2
69	Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, dju033	9.7	57
68	Detection of the prodrug-activating enzyme carboxypeptidase G2 activity with chemical exchange saturation transfer magnetic resonance. <i>Molecular Imaging and Biology</i> , <b>2014</b> , 16, 152-7	3.8	14
67	Reduced Warburg effect in cancer cells undergoing autophagy: steady-state 1H-MRS and real-time hyperpolarized 13C-MRS studies. <i>PLoS ONE</i> , <b>2014</b> , 9, e92645	3.7	17
66	Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography. <i>British Journal of Cancer</i> , <b>2014</b> , 110, 1727-32	8.7	38
65	Non-invasive molecular profiling of cancer using photoacoustic imaging of functionalized gold nanorods <b>2014</b> ,		1
64	Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma. <i>PLoS ONE</i> , <b>2014</b> , 9, e92886	3.7	14

63	Evaluation and immunohistochemical qualification of carbogen-induced $R_{21}$ as a noninvasive imaging biomarker of improved tumor oxygenation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 87, 160-7	4	14
62	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , <b>2013</b> , 15, R92	8.3	248
61	Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 1562-9	8.7	21
60	Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. <i>Cancer Cell</i> , <b>2013</b> , 24, 75-89	24.3	192
59	Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma. <i>Radiology</i> , <b>2013</b> , 266, 130-40	20.5	30
58	$^1H$ NMR and hyperpolarized $^{13}C$ NMR assays of pyruvate-lactate: a comparative study. <i>NMR in Biomedicine</i> , <b>2013</b> , 26, 1321-1325	4.4	22
57	Exploring $R(2)^*$ and $R(1)$ as imaging biomarkers of tumor oxygenation. <i>Journal of Magnetic Resonance Imaging</i> , <b>2013</b> , 38, 429-34	5.6	37
56	Model free approach to kinetic analysis of real-time hyperpolarized $^{13}C$ magnetic resonance spectroscopy data. <i>PLoS ONE</i> , <b>2013</b> , 8, e71996	3.7	116
55	Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment. <i>PLoS ONE</i> , <b>2013</b> , 8, e57641	3.7	17
54	A multi-parametric imaging investigation of the response of C6 glioma xenografts to MLN0518 (tandutinib) treatment. <i>PLoS ONE</i> , <b>2013</b> , 8, e63024	3.7	9
53	Abstract 4459: Evaluating imaging biomarkers of acquired resistance to targeted EGFR therapy in xenograft models of human squamous cell carcinoma of the head and neck (SCCHN). <b>2013</b> ,		2
52	Non-invasive in vivo imaging of vessel calibre in orthotopic prostate tumour xenografts. <i>International Journal of Cancer</i> , <b>2012</b> , 130, 1284-93	7.5	19
51	MRI measurements of vessel calibre in tumour xenografts: comparison with vascular corrosion casting. <i>Microvascular Research</i> , <b>2012</b> , 84, 323-9	3.7	13
50	Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 1854-62	7.5	9
49	The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. <i>Cancer Cell</i> , <b>2012</b> , 22, 117-30	24.3	220
48	CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 5650-61	12.9	67
47	False-negative MRI biomarkers of tumour response to targeted cancer therapeutics. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 1960-6	8.7	7
46	Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, E1267-76	11.5	25

45	The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. <i>Molecular Cancer Therapeutics</i> , <b>2011</b> , 10, 2115-23	6.1	64
44	Immunohistochemical assessment of intrinsic and extrinsic markers of hypoxia in reproductive tissue: differential expression of HIF1 $\alpha$ and HIF2 $\alpha$ in rat oviduct and endometrium. <i>Journal of Molecular Histology</i> , <b>2011</b> , 42, 341-54	3.3	11
43	Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas. <i>Journal of Pathology</i> , <b>2011</b> , 225, 344-52	9.4	25
42	Improving apparent diffusion coefficient estimates and elucidating tumor heterogeneity using Bayesian adaptive smoothing. <i>Magnetic Resonance in Medicine</i> , <b>2011</b> , 65, 438-47	4.4	21
41	Investigating temporal fluctuations in tumor vasculature with combined carbogen and ultrasmall superparamagnetic iron oxide particle (CUSPIO) imaging. <i>Magnetic Resonance in Medicine</i> , <b>2011</b> , 66, 227-34	4.4	10
40	Noninvasive detection of carboxypeptidase G2 activity in vivo. <i>NMR in Biomedicine</i> , <b>2011</b> , 24, 343-50	4.4	10
39	Intrinsic susceptibility MR imaging of chemically induced rat mammary tumors: relationship to histologic assessment of hypoxia and fibrosis. <i>Radiology</i> , <b>2010</b> , 254, 110-8	20.5	67
38	Bayesian estimation of changes in transverse relaxation rates. <i>Magnetic Resonance in Medicine</i> , <b>2010</b> , 64, 914-21	4.4	27
37	Lessons from Animal Imaging in Preclinical Models <b>2010</b> , 95-116		1
36	Robust estimation of the apparent diffusion coefficient (ADC) in heterogeneous solid tumors. <i>Magnetic Resonance in Medicine</i> , <b>2009</b> , 62, 420-9	4.4	42
35	Hyperpolarized ( <sup>13</sup> C) magnetic resonance detection of carboxypeptidase G2 activity. <i>Magnetic Resonance in Medicine</i> , <b>2009</b> , 62, 1300-4	4.4	35
34	The effects of tumor-derived platelet-derived growth factor on vascular morphology and function in vivo revealed by susceptibility MRI. <i>International Journal of Cancer</i> , <b>2008</b> , 122, 1548-56	7.5	23
33	Effect of Gd-DTPA-BMA on choline signals of HT29 tumors detected by in vivo 1H MRS. <i>Journal of Magnetic Resonance Imaging</i> , <b>2008</b> , 28, 1201-8	5.6	14
32	Longitudinal in vivo susceptibility contrast MRI measurements of LS174T colorectal liver metastasis in nude mice. <i>Journal of Magnetic Resonance Imaging</i> , <b>2008</b> , 28, 1451-8	5.6	13
31	Vessel size index magnetic resonance imaging to monitor the effect of antivasular treatment in a rodent tumor model. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 71, 1470-6	4	26
30	Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 69, 872-9	4	22
29	Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 69, 1238-45	4	14
28	Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. <i>International Journal of Radiation Biology</i> , <b>2006</b> , 82, 699-757	2.9	506

27	Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. <i>Neoplasia</i> , <b>2006</b> , 8, 199-206	6.4	32
26	The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy. <i>Neoplasia</i> , <b>2006</b> , 8, 560-7	6.4	35
25	Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126. <i>Microvascular Research</i> , <b>2006</b> , 71, 76-84	3.7	29
24	Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. <i>Neoplasia</i> , <b>2005</b> , 7, 466-74	6.4	31
23	Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. <i>Microvascular Research</i> , <b>2005</b> , 69, 56-63	3.7	23 <sup>2</sup>
22	A longitudinal study of R2* and R2 magnetic resonance imaging relaxation rate measurements in murine liver after a single administration of 3 different iron oxide-based contrast agents. <i>Investigative Radiology</i> , <b>2005</b> , 40, 784-91	10.1	31
21	The effects of tumour blood flow and oxygenation modifiers on subcutaneous tumours as determined by NIRS. <i>Advances in Experimental Medicine and Biology</i> , <b>2005</b> , 566, 75-81	3.6	5
20	Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 3705-13	12.9	32
19	Current issues in the utility of 19F nuclear magnetic resonance methodologies for the assessment of tumour hypoxia. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , <b>2004</b> , 359, 987-98 <sup>8</sup>	5.8	45
18	Tumor R2* is a prognostic indicator of acute radiotherapeutic response in rodent tumors. <i>Journal of Magnetic Resonance Imaging</i> , <b>2004</b> , 19, 482-8	5.6	84
17	In vivo determination of tumor oxygenation during growth and in response to carbogen breathing using 15C5-loaded alginate capsules as fluorine-19 magnetic resonance imaging oxygen sensors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2004</b> , 60, 909-19	4	23
16	Single dose of the antivascular agent, ZD6126 (N-acetylcolchicol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model. <i>Neoplasia</i> , <b>2004</b> , 6, 150-7	6.4	30
15	Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo. <i>Neoplasia</i> , <b>2004</b> , 6, 401-11	6.4	21
14	Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. <i>British Journal of Cancer</i> , <b>2003</b> , 88, 1592-7	8.7	105
13	Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. <i>Journal of Magnetic Resonance Imaging</i> , <b>2003</b> , 17, 445-54	5.6	124
12	Issues in GRE & SE magnetic resonance imaging to probe tumor oxygenation. <i>Advances in Experimental Medicine and Biology</i> , <b>2003</b> , 530, 441-8	3.6	6
11	Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. <i>Cancer Research</i> , <b>2003</b> , 63, 4960-6	10.1	52
10	The importance of tumor metabolism in cancer prognosis and therapy; pre-clinical studies on rodent tumors with agents that improve tumor oxygenation. <i>Advances in Enzyme Regulation</i> , <b>2002</b> , 42, 131-41		5

9	Enhanced uptake of ifosfamide into GH3 prolactinomas with hypercapnic hyperoxic gases monitored in vivo by (31)P MRS. <i>Neoplasia</i> , <b>2002</b> , 4, 539-43	6.4	8
8	Effects of different levels of hypercapnic hyperoxia on tumour R(2)* and arterial blood gases. <i>Magnetic Resonance Imaging</i> , <b>2001</b> , 19, 161-6	3.3	39
7	Applications of magnetic resonance in model systems: tumor biology and physiology. <i>Neoplasia</i> , <b>2000</b> , 2, 139-51	6.4	100
6	Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. <i>NMR in Biomedicine</i> , <b>1999</b> , 12, 98-106	4.4	76
5	Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging <b>1999</b> , 12, 98		1
4	Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow. <i>Seminars in Radiation Oncology</i> , <b>1998</b> , 8, 197-207	5.5	69
3	The response of human tumors to carbogen breathing, monitored by Gradient-Recalled Echo Magnetic Resonance Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1997</b> , 39, 697-701	4.1	119
2	Modification of tumour perfusion and oxygenation monitored by gradient recalled echo MRI and 31P MRS. <i>NMR in Biomedicine</i> , <b>1996</b> , 9, 208-16	4.4	23
1	Noninvasive monitoring of carbogen-induced changes in tumor blood flow and oxygenation by functional magnetic resonance imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1995</b> , 33, 855-9	4	108